These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 37072219

  • 21. Predictors of Health Utility in Relapsing-Remitting and Secondary-Progressive Multiple Sclerosis: Implications for Future Economic Models of Disease-Modifying Therapies.
    Hernandez L, O'Donnell M, Postma M, for MSOAC.
    Pharmacoeconomics; 2021 Feb; 39(2):243-256. PubMed ID: 32989685
    [Abstract] [Full Text] [Related]

  • 22. Inclusion of the Symbol Digit Modalities Test in a revised assessment of 'no evidence of disease activity-4 (NEDA-4)' in Latin-American patients with multiple sclerosis.
    Guevara C, Villa E, Diaz V, Garrido C, Martinez M, Orellana P, Alarcón P, Silva-Rosas C, Barker GJ, Kempton MJ, de Grazia J.
    Mult Scler Relat Disord; 2020 Jul; 42():102076. PubMed ID: 32361478
    [Abstract] [Full Text] [Related]

  • 23. Efficacy of Computerized vs. Traditional Cognitive Interventions for the Treatment of Chronic mTBI Symptoms Among Service Members.
    Darr AJ, Babakhanyan I, Caswell M, Alia Westphal B, Bailie JM.
    Mil Med; 2024 Aug 19; 189(Suppl 3):530-538. PubMed ID: 39160812
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Correlation between cognitive changes and neuroradiological changes over time in multiple sclerosis: a systematic review and meta-analysis.
    Simani L, Molaeipour L, Kian S, Leavitt VM.
    J Neurol; 2024 Aug 19; 271(8):5498-5518. PubMed ID: 38890188
    [Abstract] [Full Text] [Related]

  • 26. Trail Making Test Could Predict Impairment in Cognitive Domains in Patients with Multiple Sclerosis: A Study of Diagnostic Accuracy.
    Kabiri S, Jameie M, Balali P, Adib Moradi S, Sanjari Moghaddam H, Aghamollaii V, Harirchian MH.
    Arch Clin Neuropsychol; 2023 Jan 21; 38(1):37-48. PubMed ID: 35901460
    [Abstract] [Full Text] [Related]

  • 27. Cognitive impairment and decline in different MS subtypes.
    Huijbregts SC, Kalkers NF, de Sonneville LM, de Groot V, Polman CH.
    J Neurol Sci; 2006 Jun 15; 245(1-2):187-94. PubMed ID: 16643951
    [Abstract] [Full Text] [Related]

  • 28. Baseline characteristics and effects of fingolimod on cognitive performance in patients with relapsing-remitting multiple sclerosis.
    Langdon DW, Tomic D, Penner IK, Calabrese P, Cutter G, Häring DA, Dahlke F, Kappos L.
    Eur J Neurol; 2021 Dec 15; 28(12):4135-4145. PubMed ID: 34431170
    [Abstract] [Full Text] [Related]

  • 29. Recovery of cognitive function after relapse in multiple sclerosis.
    Benedict RH, Pol J, Yasin F, Hojnacki D, Kolb C, Eckert S, Tacca B, Drake A, Wojcik C, Morrow SA, Jakimovski D, Fuchs TA, Dwyer MG, Zivadinov R, Weinstock-Guttman B.
    Mult Scler; 2021 Jan 15; 27(1):71-78. PubMed ID: 31971066
    [Abstract] [Full Text] [Related]

  • 30. The Multiple Sclerosis Functional Composite and Symbol Digit Modalities Test as outcome measures in pediatric multiple sclerosis.
    Brenton JN, Koshiya H, Woolbright E, Goldman MD.
    Mult Scler J Exp Transl Clin; 2019 Jan 15; 5(2):2055217319846141. PubMed ID: 31065380
    [Abstract] [Full Text] [Related]

  • 31. Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test.
    Drake AS, Weinstock-Guttman B, Morrow SA, Hojnacki D, Munschauer FE, Benedict RH.
    Mult Scler; 2010 Feb 15; 16(2):228-37. PubMed ID: 20028710
    [Abstract] [Full Text] [Related]

  • 32. Cortical surface thickness, subcortical volumes and disability between races in relapsing-remitting multiple sclerosis.
    Bross M, Hackett M, Bernitsas MM, Bao F, Carla-Santiago-Martinez, Bernitsas E.
    Mult Scler Relat Disord; 2021 Aug 15; 53():103025. PubMed ID: 34052742
    [Abstract] [Full Text] [Related]

  • 33. Clinical features of sleep apnea syndrome and cognitive impairment in multiple sclerosis.
    Terauchi T, Mizuno M, Suzuki M, Akasaka H, Maeta M, Tamura K, Hosokawa K, Nishijima T, Maeda T.
    Mult Scler Relat Disord; 2024 Feb 15; 82():105407. PubMed ID: 38160637
    [Abstract] [Full Text] [Related]

  • 34. Interpreting change on the Symbol Digit Modalities Test in people with relapsing multiple sclerosis using the reliable change methodology.
    Weinstock Z, Morrow S, Conway D, Fuchs T, Wojcik C, Unverdi M, Zivadinov R, Weinstock-Guttman B, Iverson GL, Dwyer M, Benedict RH.
    Mult Scler; 2022 Jun 15; 28(7):1101-1111. PubMed ID: 34612114
    [Abstract] [Full Text] [Related]

  • 35. Thalamic-hippocampal-prefrontal disruption in relapsing-remitting multiple sclerosis.
    Kern KC, Gold SM, Lee B, Montag M, Horsfall J, O'Connor MF, Sicotte NL.
    Neuroimage Clin; 2015 Jun 15; 8():440-7. PubMed ID: 26106524
    [Abstract] [Full Text] [Related]

  • 36. Effects of single dose mixed amphetamine salts--extended release on processing speed in multiple sclerosis: a double blind placebo controlled study.
    Morrow SA, Rosehart H.
    Psychopharmacology (Berl); 2015 Dec 15; 232(23):4253-9. PubMed ID: 26289355
    [Abstract] [Full Text] [Related]

  • 37. Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE.
    Perumal J, Fox RJ, Balabanov R, Balcer LJ, Galetta S, Makh S, Santra S, Hotermans C, Lee L.
    BMC Neurol; 2019 Jun 08; 19(1):116. PubMed ID: 31176355
    [Abstract] [Full Text] [Related]

  • 38. High levels of kappa free light chain synthesis predict cognitive decline in relapsing-remitting multiple sclerosis.
    Rosenstein I, Axelsson M, Novakova L, Rasch S, Blennow K, Zetterberg H, Lycke J.
    Front Immunol; 2023 Jun 08; 14():1106028. PubMed ID: 36742305
    [Abstract] [Full Text] [Related]

  • 39. [Information processing speed and influential factors in multiple sclerosis].
    Zhang ML, Xu EH, Dong HQ, Zhang JW.
    Zhonghua Yi Xue Za Zhi; 2016 Apr 19; 96(15):1173-7. PubMed ID: 27117362
    [Abstract] [Full Text] [Related]

  • 40. Measures of Thalamic Integrity are Associated with Cognitive Functioning in Fingolimod-treated Multiple Sclerosis Patients.
    Conway DS, Planchon SM, Oh SH, Nakamura K, Thompson NR, Sakaie K, Ontaneda D.
    Mult Scler Relat Disord; 2021 Jan 19; 47():102635. PubMed ID: 33260053
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.